Stay updated with breaking news from Dmitry Samarsky. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Sirnaomics Ltd. (the "Company"; stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical...
/PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK) a leading biopharmaceutical company in discovery and development of RNAi...
/PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi...
/PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi...
GAITHERSBURG, Md. and SUZHOU, China, June 22, 2022 /PRNewswire/ -- Sirnaomics Ltd.(the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that the Company's Chief Technology Officer, Dmitry Samarsky, PhD, will present the latest developments and expanded applications of its Dual-Targeted RNAi therapeutics based on its proprietary GalAhead technology and product pipeline, at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium. The Symposium will take place virtuall...